{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:17:36Z","timestamp":1773875856811,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002531","name":"Kyungpook National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.intimp.2020.106398","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T21:04:44Z","timestamp":1584479084000},"page":"106398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation"],"prefix":"10.1016","volume":"83","author":[{"given":"Young-Ae","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Kyeong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong-Cheol","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hima","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeg Kyu","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwoo","family":"Khang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12566","article-title":"Introduction to \u201callergic inflammation\u201d","volume":"278","author":"Nakayama","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2020.106398_b0010","article-title":"Mast cell activation syndrome","author":"Frieri","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199957010-00004","article-title":"Second-generation antihistamines","volume":"57","author":"Slater","year":"1999","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.intimp.2020.106398_b0020","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s40265-013-0095-2","article-title":"Dabrafenib: first global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.intimp.2020.106398_b0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/ml4000063","article-title":"Discovery of Dabrafenib: a selective inhibitor of raf kinases with antitumor activity against B-Raf-Driven Tumors","volume":"4","author":"Rheault","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.intimp.2020.106398_b0030","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2020.106398_b0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1139\/cjpp-2016-0519","article-title":"Anti-inflammatory effects of dabrafenib in vitro and in vivo","volume":"95","author":"Lee","year":"2017","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.intimp.2020.106398_b0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cbi.2016.07.024","article-title":"Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption","volume":"256","author":"Lee","year":"2016","journal-title":"Chem. Biol. Interact."},{"issue":"4","key":"10.1016\/j.intimp.2020.106398_b0045","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5483\/BMBRep.2016.49.4.220","article-title":"Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses","volume":"49","author":"Jung","year":"2016","journal-title":"BMB Rep."},{"issue":"2","key":"10.1016\/j.intimp.2020.106398_b0050","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12272-016-0869-7","article-title":"Suppressive effects of dabrafenib on endothelial protein C receptor shedding","volume":"40","author":"Ku","year":"2017","journal-title":"Arch. Pharm. Res."},{"issue":"7","key":"10.1016\/j.intimp.2020.106398_b0055","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri3690","article-title":"Mast cell secretory granules: armed for battle","volume":"14","author":"Wernersson","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106398_b0060","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1142\/S0192415X15500573","article-title":"Ameliorative effect of aspalathin and nothofagin from rooibos (Aspalathus linearis) on HMGB1-induced septic responses in vitro and in vivo","volume":"43","author":"Lee","year":"2015","journal-title":"Am. J. Chin. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10753-014-0049-1","article-title":"Aspalathin and Nothofagin from Rooibos (Aspalathus linearis) inhibits high glucose-induced inflammation in vitro and in vivo","volume":"38","author":"Ku","year":"2015","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.intimp.2020.106398_b0070","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1007\/s10753-015-0125-1","article-title":"Anti-inflammatory effects of aspalathin and nothofagin from rooibos (Aspalathus linearis) in vitro and in vivo","volume":"38","author":"Lee","year":"2015","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12634","article-title":"Mast cells as sources of cytokines, chemokines, and growth factors","volume":"282","author":"Mukai","year":"2018","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2020.106398_b0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0091-6749(97)70131-3","article-title":"The protooncogene c-kit and c-kit ligand in human disease","volume":"100","author":"Vliagoftis","year":"1997","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106398_b0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1096\/fj.01-0766fje","article-title":"B-Raf\/Rap1 signaling, but not c-Raf-1\/Ras, induces the histidine decarboxylase promoter in Helicobacter pylori infection","volume":"16","author":"Wessler","year":"2002","journal-title":"FASEB J."},{"issue":"42","key":"10.1016\/j.intimp.2020.106398_b0090","doi-asserted-by":"crossref","first-page":"E9859","DOI":"10.1073\/pnas.1805474115","article-title":"Raf kinase inhibitor protein negatively regulates FcepsilonRI-mediated mast cell activation and allergic response","volume":"115","author":"Lin","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2020.106398_b0095","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fphar.2018.00591","article-title":"Elaeocarpusin inhibits mast cell-mediated allergic inflammation","volume":"9","author":"Kim","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2020.106398_b0100","article-title":"Association between perfluorooctanoic acid exposure and degranulation of mast cells in allergic inflammation","author":"Lee","year":"2016","journal-title":"J. Appl. Toxicol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106398_b0105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1535370214555663","article-title":"SG-HQ2 inhibits mast cell-mediated allergic inflammation through suppression of histamine release and pro-inflammatory cytokines","volume":"240","author":"Je","year":"2015","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"4","key":"10.1016\/j.intimp.2020.106398_b0110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"3","key":"10.1016\/j.intimp.2020.106398_b0115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.taap.2013.12.006","article-title":"Inhibitory effect of putranjivain A on allergic inflammation through suppression of mast cell activation","volume":"274","author":"Kim","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/aps.2016.112","article-title":"2-Hydroxy-3-methoxybenzoic acid attenuates mast cell-mediated allergic reaction in mice via modulation of the FcepsilonRI signaling pathway","volume":"38","author":"Kim","year":"2017","journal-title":"Acta. Pharmacol. Sin."},{"issue":"11","key":"10.1016\/j.intimp.2020.106398_b0125","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ni.f.216","article-title":"New developments in mast cell biology","volume":"9","author":"Kalesnikoff","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2020.106398_b0130","first-page":"620","article-title":"Mast cell: A multi-functional master cell","volume":"6","author":"Krystel-Whittemore","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2020.106398_b0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2018.03.035","article-title":"Furaltadone suppresses IgE-mediated allergic response through the inhibition of Lyn\/Syk pathway in mast cells","volume":"828","author":"Nam","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2020.106398_b0140","first-page":"e52005","article-title":"Measuring local anaphylaxis in mice","volume":"92","author":"Evans","year":"2014","journal-title":"J. Vis. Exp."},{"issue":"8","key":"10.1016\/j.intimp.2020.106398_b0145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7203","key":"10.1016\/j.intimp.2020.106398_b0150","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature07204","article-title":"The development of allergic inflammation","volume":"454","author":"Galli","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbadis.2010.12.014","article-title":"Mast cells and inflammation","volume":"1822","author":"Theoharides","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.intimp.2020.106398_b0160","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/eji.201444546","article-title":"Mast cell activation: a complex interplay of positive and negative signaling pathways","volume":"44","author":"Sibilano","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106398_b0165","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2015.05.010","article-title":"T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production","volume":"75","author":"Zhu","year":"2015","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.intimp.2020.106398_b0175","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri3831","article-title":"Type 2 cytokines: mechanisms and therapeutic strategies","volume":"15","author":"Wynn","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0180","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2015.05.014","article-title":"IL-4 and IL-13 signaling in allergic airway disease","volume":"75","author":"Gour","year":"2015","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.intimp.2020.106398_b0185","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.4049\/jimmunol.169.9.5287","article-title":"NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells?","volume":"169","author":"Coward","year":"2002","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014525","article-title":"Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils","volume":"6","author":"Zhang","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.intimp.2020.106398_b0195","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1189\/jlb.0412214","article-title":"Regulation of inflammation by interleukin-4: a review of \u201calternatives\u201d","volume":"92","author":"Luzina","year":"2012","journal-title":"J. Leukoc. Biol."},{"issue":"9","key":"10.1016\/j.intimp.2020.106398_b0200","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1084\/jem.20170910","article-title":"The transcriptional program, functional heterogeneity, and clinical targeting of mast cells","volume":"214","author":"Cildir","year":"2017","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.intimp.2020.106398_b0205","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2174\/138161212800165997","article-title":"Mast cells in allergic and inflammatory diseases","volume":"18","author":"Sismanopoulos","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.intimp.2020.106398_b0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1042\/BSR20110089","article-title":"Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion","volume":"32","author":"Turner","year":"2012","journal-title":"Biosci. Rep."},{"issue":"9","key":"10.1016\/j.intimp.2020.106398_b0215","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri2818","article-title":"NFAT, immunity and cancer: a transcription factor comes of age","volume":"10","author":"Muller","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106398_b0220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1590\/S0100-879X2005000300003","article-title":"NFAT transcription factors: from cell cycle to tumor development","volume":"38","author":"Viola","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"18","key":"10.1016\/j.intimp.2020.106398_b0225","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1101\/gad.1102703","article-title":"Transcriptional regulation by calcium, calcineurin, and NFAT","volume":"17","author":"Hogan","year":"2003","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.intimp.2020.106398_b0230","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.aller.2016.01.001","article-title":"Singh, Ovalbumin-induced allergic inflammation lead to structural alterations in mouse model and protective effects of intranasal curcumin: a comparative study","volume":"44","author":"Subhashini","year":"2016","journal-title":"Allergol. Immunopathol. (Madr)"},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CMR.0000000000000529","article-title":"Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test","volume":"29","author":"Seremet","year":"2019","journal-title":"Melanoma Res."},{"issue":"11","key":"10.1016\/j.intimp.2020.106398_b0240","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.annder.2019.08.012","article-title":"Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors","volume":"146","author":"Rohmer","year":"2019","journal-title":"Ann. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106398_b0245","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1203475416670368","article-title":"Prospective case series of cutaneous adverse effects associated with dabrafenib and trametinib","volume":"21","author":"Lacroix","year":"2017","journal-title":"J. Cutan. Med. Surg."},{"issue":"7","key":"10.1016\/j.intimp.2020.106398_b0250","doi-asserted-by":"crossref","first-page":"e1052212","DOI":"10.1080\/2162402X.2015.1052212","article-title":"Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma","volume":"5","author":"Homet Moreno","year":"2016","journal-title":"Oncoimmunology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920302162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920302162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:19:25Z","timestamp":1761585565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920302162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":50,"alternative-id":["S1567576920302162"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106398","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106398"}}